In fact, the recent purchase by President Jay Venkatesan was not their only acquisition of Angion Biomedica shares this year. They previously made an even bigger purchase of US$730k worth of shares at ...
UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small ...
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Angion Biomedica Corp. (NASDAQ: ANGN) today announced the discontinuation of JUNIPER, ...
ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the ...
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a ...
Angion Biomedica announced positive phase II clinical trial results for its drug ANG-3777, which treats acute kidney injuries. The study tested whether the small molecule could help kidney transplant ...
UNIONDALE, N.Y.--(BUSINESS WIRE)--Angion Biomedica Corp. announced today that it plans to commence enrollment of a Phase 3 clinical trial using its investigational drug BB3 to treat delayed graft ...
UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Please provide your email address to receive an email when new articles are posted on . Angion Biomedica Corp. has signed a licensing agreement with Vifor Pharma for the commercialization of ANG-3777, ...
Cancer immunotherapy developer Elicio Therapeutics is finally getting a listing on the public markets to finance its clinical research. But rather than the traditional IPO it had been seeking, the ...
Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results